Empowered Patient Podcast

Derek Streat, Founder and CEO of DexCare, has created an orchestration platform that helps manage healthcare's demand and supply sides. As a data-driven intelligence company, the focus is on allocating limited resources to drive maximum productive utilization for all stakeholders. While there are often conflicting goals, using large data sets, risk models can be developed to meet the needs of patients, providers, and payers and better manage access to and cost of healthcare.

Derek explains, "For the benefit of providers, patients, and health systems, those resources must be allocated. Those precious resources, with limited time and quantity, need to be allocated in a way that makes them the most productive utilization of those resources. We all know that, again, the reason that we often have to wait a long time to get access to care. Whether it's sitting in a waiting room in an ED or waiting weeks or months to get access to a specialist, the reason that happens is often there's a misallocation or misalignment of how those resources are allocated to patients. We figured out a way to do that better so that the capacity of those resources can be extended in a way to service more patients."

"The sad reality of one of the major rate limiters in healthcare access these days is that there aren't enough skilled people around to take care of all the people that need to be taken care of. And with an aging population and people living longer and all those things, the human resources we have only go so far. This is also in the face of declining numbers, declining enrollments in medical institutions, etc. And so, you've got to have technology to help extend the capacity of doctors, nurses, and so forth, who are taking care of folks."

#DexCare #SocialDeterminantsofHealth #SDOH #AccesstoCare #VirtualCare

dexcare.com

Listen to the podcast here

Derek Streat, Founder and CEO of DexCare, has created an orchestration platform that helps manage healthcare's demand and supply sides. As a data-driven intelligence company, the focus is on allocating limited resources to drive maximum productive utilization for all stakeholders. While there are often conflicting goals, using large data sets, risk models can be developed to meet the needs of patients, providers, and payers and better manage access to and cost of healthcare.

Derek explains, "For the benefit of providers, patients, and health systems, those resources must be allocated. Those precious resources, with limited time and quantity, need to be allocated in a way that makes them the most productive utilization of those resources. We all know that, again, the reason that we often have to wait a long time to get access to care. Whether it's sitting in a waiting room in an ED or waiting weeks or months to get access to a specialist, the reason that happens is often there's a misallocation or misalignment of how those resources are allocated to patients. We figured out a way to do that better so that the capacity of those resources can be extended in a way to service more patients."

"The sad reality of one of the major rate limiters in healthcare access these days is that there aren't enough skilled people around to take care of all the people that need to be taken care of. And with an aging population and people living longer and all those things, the human resources we have only go so far. This is also in the face of declining numbers, declining enrollments in medical institutions, etc. And so, you've got to have technology to help extend the capacity of doctors, nurses, and so forth, who are taking care of folks."

#DexCare #SocialDeterminantsofHealth #SDOH #AccesstoCare #VirtualCare

dexcare.com

Download the transcript here

Dr. Carol DerSarkissian, Medical Director at Ezra, is bringing AI-enhanced MRI technology to a broader market to help detect cancer earlier in vulnerable and asymptomatic populations. Using Ezra Flash and a high-speed MRI protocol, MRIs are performed quickly and enhanced to provide high-quality images at the limits of the current standard of care for review by expert radiologists. The Ezra Flash scan is a full body scan now priced at $1,350, with a goal of $500.

Carol elaborates, "The goal is early detection, which is one of our best tools in fighting cancer. Early cancer detection has about an 80% survival rate, compared to less than 20% for late-stage cancer. These statistics are from the American Cancer Society. Yet 50% of cancers are still detected at a late stage. There is a need. At Ezra, we're the first company to leverage artificial intelligence globally, AI across all three key components of the cancer screening process: one, imaging, two, analysis, and three, reporting and making it available directly to consumers."

"Right now, the Ezra scan is not covered by insurance. However, as we're moving towards making it a faster, shorter scan, that will help the insurance companies cover it. In terms of AI and mammograms, when computer-assisted detection came out, that was an AI with a smaller database. Initially, it wasn't covered by insurance, but then they saw the utility of it, and it was covered by insurance. It is a direction we're moving in as more and more data and more and more evidence is accumulated."

#CancerDetection #ProactiveScreening #AIinHealthcare #CancerScreening #FullBodyScan #WholeBodyScan #MRI #MRIScreening

ezra.com

Listen to the podcast here

Dr. Carol DerSarkissian, Medical Director at Ezra, is bringing AI-enhanced MRI technology to a broader market to help detect cancer earlier in vulnerable and asymptomatic populations. Using Ezra Flash and a high-speed MRI protocol, MRIs are performed quickly and enhanced to provide high-quality images at the limits of the current standard of care for review by expert radiologists. The Ezra Flash scan is a full body scan now priced at $1,350, with a goal of $500.

Carol elaborates, "The goal is early detection, which is one of our best tools in fighting cancer. Early cancer detection has about an 80% survival rate, compared to less than 20% for late-stage cancer. These statistics are from the American Cancer Society. Yet 50% of cancers are still detected at a late stage. There is a need. At Ezra, we're the first company to leverage artificial intelligence globally, AI across all three key components of the cancer screening process: one, imaging, two, analysis, and three, reporting and making it available directly to consumers."

"Right now, the Ezra scan is not covered by insurance. However, as we're moving towards making it a faster, shorter scan, that will help the insurance companies cover it. In terms of AI and mammograms, when computer-assisted detection came out, that was an AI with a smaller database. Initially, it wasn't covered by insurance, but then they saw the utility of it, and it was covered by insurance. It is a direction we're moving in as more and more data and more and more evidence is accumulated."

#CancerDetection #ProactiveScreening #AIinHealthcare #CancerScreening #FullBodyScan #WholeBodyScan #MRI #MRIScreening

ezra.com

Download the transcript here

Dr. Nora Zetsche, Co-Founder and Chief Medical Officer of Veta Health, a health tech company, has designed a continuous support solution for patients that includes virtual care and virtual support of in-person care. Remote monitoring includes patient-reported data, text messages, tracking from wearables and other passive sensors. Integrating existing electronic health records allows providers to incorporate the virtual data to enable clinicians to make appropriate treatment decisions.

Nora explains, "It's always tricky with these buzzwords in health tech because everyone ends up having a different interpretation of them. And so, for us, remote monitoring isn't just what came about in the pandemic, which is these reimbursement codes around remote patient monitoring. Still, it's a whole gamut of virtual care extension into patients' homes. And a part of that is how we seamlessly get information from the patient to the caring clinicians."

"And that is, for us, that remote monitoring, that on the one hand, entails the data from wearables that may be collected passively. It can contain survey data from the patient directly, patient-reported outcome data, and the interactions that clinical teams and clinical staff have with the patient as the patient is at home. This can be done asynchronously through text messages, secure messaging, and synchronously through telehealth. So it's the rest of how we get better insights into how the patients are doing in their homes or outside of clinical settings and how we better use those insights to support these patients."

"There's a huge fear of just a sea of data you have to wade through to get insight into the patients. And that's never been our intention. We don't just collect data for the sake of collecting data and then give it in raw format to the clinicians. Our software platform has analytics and workflow tools to parse through the data, figure out which data is relevant for a clinician and a given patient at a given time, and prioritize that data for the clinicians. It gives the clinicians additional context to that data."

#VetaHealth #HealthTech #RemoteMonitoring #MachineLearning #DigitalCare #VirtualCare

myvetahealth.com

Listen to the podcast here

Dr. Nora Zetsche, Co-Founder and Chief Medical Officer of Veta Health, a health tech company, has designed a continuous support solution for patients that includes virtual care and virtual support of in-person care. Remote monitoring includes patient-reported data, text messages, tracking from wearables and other passive sensors. Integrating existing electronic health records allows providers to incorporate the virtual data to enable clinicians to make appropriate treatment decisions.

Nora explains, "It's always tricky with these buzzwords in health tech because everyone ends up having a different interpretation of them. And so, for us, remote monitoring isn't just what came about in the pandemic, which is these reimbursement codes around remote patient monitoring. Still, it's a whole gamut of virtual care extension into patients' homes. And a part of that is how we seamlessly get information from the patient to the caring clinicians."

"And that is, for us, that remote monitoring, that on the one hand, entails the data from wearables that may be collected passively. It can contain survey data from the patient directly, patient-reported outcome data, and the interactions that clinical teams and clinical staff have with the patient as the patient is at home. This can be done asynchronously through text messages, secure messaging, and synchronously through telehealth. So it's the rest of how we get better insights into how the patients are doing in their homes or outside of clinical settings and how we better use those insights to support these patients."

"There's a huge fear of just a sea of data you have to wade through to get insight into the patients. And that's never been our intention. We don't just collect data for the sake of collecting data and then give it in raw format to the clinicians. Our software platform has analytics and workflow tools to parse through the data, figure out which data is relevant for a clinician and a given patient at a given time, and prioritize that data for the clinicians. It gives the clinicians additional context to that data."

#VetaHealth #HealthTech #RemoteMonitoring #MachineLearning #DigitalCare #VirtualCare

myvetahealth.com

Download the transcript here

Dror Zur, Founder and CEO of MAGENTIQ EYE, discusses the opportunities for reducing the risk of colorectal cancer through AI-assisted colonoscopies. He points out the relatively high polyp miss rate that can be due to the size of the polyp, interpretations by physicians, and limitations of the procedure room. The MAGENTIQ-Colo AI system analyzes colonoscopy videos in real time and alerts the physician to polyps with a bounding box.

Dror explains, "The procedure room is not a perfect place. There is some noise, and there are other people sometimes. There can be interference. Also, sometimes, the polyp passes through the video very fast, and even if it is not a very small polyp, it's hard to detect it. Sometimes, the point-of-view is such that it is hard to see. Sometimes, it is hidden behind a fold or something like that, and then only a very small part of it can be seen. It is hard to detect the polyp this way. There are several reasons for that."

"The system takes the video, breaks it into frames, and analyzes each frame by the AI engine of the system, detects polyps if they are there, and shows the bounding box on the video where the physician is looking. It actually doesn't change anything in the clinical workflow. The procedure stays exactly the same. You just have additional information, which is decision support information for the physician that helps them to decide if there is a polyp. It is just plug-and-play. The installation is very simple."

"This is, by the way, done by doing two colonoscopy tests, one immediately after the other with the same patient, and what is being detected in the second one is the miss rate of the first one, polyps that were not detected in the first one. It's called adenoma miss rate, the percentage of missed adenomas. The study showed a relative increase of 37% in the adenoma per colonoscopy, the average number of adenomas that are detected, and the miss rate is cut almost by half."

#MAGENTIQEYE #AIHealthcare #ColorectalHealth #ColorectalCancer #HealthScreening #MedicalInnovation #HealthTechAdvancements #PatientAdvocacy #CancerPrevention #PatientExperience #FutureofHealthcare #MedicalResearch

magentiq.com

Listen to the podcast here

Dror Zur, Founder and CEO of MAGENTIQ EYE, discusses the opportunities for reducing the risk of colorectal cancer through AI-assisted colonoscopies. He points out the relatively high polyp miss rate that can be due to the size of the polyp, interpretations by physicians, and limitations of the procedure room. The MAGENTIQ-Colo AI system analyzes colonoscopy videos in real time and alerts the physician to polyps with a bounding box.

Dror explains, "The procedure room is not a perfect place. There is some noise, and there are other people sometimes. There can be interference. Also, sometimes, the polyp passes through the video very fast, and even if it is not a very small polyp, it's hard to detect it. Sometimes, the point-of-view is such that it is hard to see. Sometimes, it is hidden behind a fold or something like that, and then only a very small part of it can be seen. It is hard to detect the polyp this way. There are several reasons for that."

"The system takes the video, breaks it into frames, and analyzes each frame by the AI engine of the system, detects polyps if they are there, and shows the bounding box on the video where the physician is looking. It actually doesn't change anything in the clinical workflow. The procedure stays exactly the same. You just have additional information, which is decision support information for the physician that helps them to decide if there is a polyp. It is just plug-and-play. The installation is very simple."

"This is, by the way, done by doing two colonoscopy tests, one immediately after the other with the same patient, and what is being detected in the second one is the miss rate of the first one, polyps that were not detected in the first one. It's called adenoma miss rate, the percentage of missed adenomas. The study showed a relative increase of 37% in the adenoma per colonoscopy, the average number of adenomas that are detected, and the miss rate is cut almost by half."

#MAGENTIQEYE #AIHealthcare #ColorectalHealth #ColorectalCancer #HealthScreening #MedicalInnovation #HealthTechAdvancements #PatientAdvocacy #CancerPrevention #PatientExperience #FutureofHealthcare #MedicalResearch

magentiq.com

Download the transcript here

Dr. Eliseo Salinas, head of Research and Development at Delix Therapeutics, is focused on developing drugs to treat central nervous system disorders by addressing synaptic density. Applying knowledge about psychoplastogens and neuroplastogens, Delix strives to increase connections between neurons in treating depression more quickly and effectively than using antidepressants.

Eliseo explains, "The term psychoplastogen was coined only a few years ago when it was realized that certain substances, like ketamine or psychedelics like psilocybin, produce those increases in synaptic density in hours, not weeks. So, those were termed psychoplastogens. More recently, it is believed that the psychedelics or psychotomimetic effects of those psychoplastogens might not be necessary for the therapeutic benefit."

"Neuroplastogens are those compounds that produce an acute increase in synaptic density in hours without producing those psychotomimetics or hallucinatory effects that the typical psychedelics produce."

"When you look at the psychoplastogens, the drugs that induce those rapid increases in synaptic density, they are not all the same. So, for example, you have one that is psilocybin, which is in the magic mushrooms. That substance produces hallucination, typical hallucinations, a trip where the person or patient has a vivid hallucinatory experience. But there are others, like ketamine, that don't produce that type of hallucination. They rarely produce hallucination. Ketamine is a dissociative agent where you feel strange or sedated and sleep for a few hours, but not typically hallucinations. And finally, the most striking difference is the effect of electroconvulsive therapy, ECT, or electroshock. In animals, electroshock does exactly the same thing as ketamine and psilocybin or LSD, producing an increase in synaptic density in hours, but it doesn't produce hallucinations or dissociations."

#DelixTherapeutics #Neuroplastogen #Psychoplastogen #Neuroplasticity #MentalHealth #Biotech #HealtheMind

DelixTherapeutics.com

Listen to the podcast here

Dr. Eliseo Salinas, head of Research and Development at Delix Therapeutics, is focused on developing drugs to treat central nervous system disorders by addressing synaptic density. Applying knowledge about psychoplastogens and neuroplastogens, Delix strives to increase connections between neurons in treating depression more quickly and effectively than using antidepressants.

Eliseo explains, "The term psychoplastogen was coined only a few years ago when it was realized that certain substances, like ketamine or psychedelics like psilocybin, produce those increases in synaptic density in hours, not weeks. So, those were termed psychoplastogens. More recently, it is believed that the psychedelics or psychotomimetic effects of those psychoplastogens might not be necessary for the therapeutic benefit."

"Neuroplastogens are those compounds that produce an acute increase in synaptic density in hours without producing those psychotomimetics or hallucinatory effects that the typical psychedelics produce."

"When you look at the psychoplastogens, the drugs that induce those rapid increases in synaptic density, they are not all the same. So, for example, you have one that is psilocybin, which is in the magic mushrooms. That substance produces hallucination, typical hallucinations, a trip where the person or patient has a vivid hallucinatory experience. But there are others, like ketamine, that don't produce that type of hallucination. They rarely produce hallucination. Ketamine is a dissociative agent where you feel strange or sedated and sleep for a few hours, but not typically hallucinations. And finally, the most striking difference is the effect of electroconvulsive therapy, ECT, or electroshock. In animals, electroshock does exactly the same thing as ketamine and psilocybin or LSD, producing an increase in synaptic density in hours, but it doesn't produce hallucinations or dissociations."

#DelixTherapeutics #Neuroplastogen #Psychoplastogen #Neuroplasticity #MentalHealth #Biotech #HealtheMind

DelixTherapeutics.com

Download the transcript here